The Trump administration's proposed cuts at the NIH and FDA could lower the number of new drugs that come to market in the next three decades, according to a CBO analysis. Under hypothetical scenarios of a permanent 10% budget cut to the NIH and a nine-month drug review delay at the FDA due to staffing cuts, an estimated 53 drugs would not come to market over that time span, the budget office found. The analysis, requested by Senate and House Democrats, will likely become a main talking point for them during the fiscal 2026 appropriations process.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
